Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0U0QI
|
||||
| Former ID |
DIB006006
|
||||
| Drug Name |
GYKI-16084
|
||||
| Synonyms |
Uroflux; IDR-16084; (+)-(R)-2-[3-(Benzo-1,4-dioxan-2-ylmethylamino)propyl]pyridazin-3(2H)-one hydrochloride
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Prostate disease [ICD10:N42.9] | Discontinued in Phase 2 | [546866] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H19N3O3
|
||||
| Canonical SMILES |
C1C(OC2=CC=CC=C2O1)CNCCCN3C(=O)C=CC=N3
|
||||
| InChI |
1S/C16H19N3O3/c20-16-7-3-9-18-19(16)10-4-8-17-11-13-12-21-14-5-1-2-6-15(14)22-13/h1-3,5-7,9,13,17H,4,8,10-12H2/t13-/m1/s1
|
||||
| InChIKey |
FJNRJBQUOQLUNQ-CYBMUJFWSA-N
|
||||
| CAS Number |
CAS 185739-21-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Alpha-2C adrenergic receptor | Target Info | Antagonist | [528199] | |
| Alpha-1D adrenergic receptor | Target Info | Antagonist | [528199] | ||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| Reactome | Adrenoceptors | ||||
| Adrenaline signalling through Alpha-2 adrenergic receptor | |||||
| Adrenaline,noradrenaline inhibits insulin secretion | |||||
| G alpha (i) signalling events | |||||
| G alpha (z) signalling events | |||||
| Surfactant metabolismR-HSA-390696:Adrenoceptors | |||||
| G alpha (q) signalling events | |||||
| G alpha (12/13) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Platelet Aggregation (Plug Formation) | |||||
| Integration of energy metabolism | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP58:Monoamine GPCRs | |||||
| Calcium Regulation in the Cardiac Cell | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.